Ahmad Elayyan, MD
Endocrinology, Diabetes & Metabolism · Millsboro, DENPI 1366884785
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 216 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,389 and has fallen 59.3% since, to $565 in 2025.
Across 216 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$827
- Lilly USA, LLC$506
- Amgen$399
- Sanofi-aventis U.S. LLC$355
- Abbott$336
- Corcept Therapeutics$316
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$130%
- Food & beverage$4,32099%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 59 | $827 |
| Lilly USA, LLC | 20 | $506 |
| Amgen | 11 | $399 |
| Sanofi-aventis U.S. LLC | 17 | $355 |
| Abbott | 20 | $336 |
| Corcept Therapeutics | 11 | $316 |
| AstraZeneca | 16 | $271 |
| Dexcom, Inc. | 6 | $189 |
| Boehringer Ingelheim | 9 | $158 |
| Akcea Therapeutics, Inc. | 2 | $106 |
| Bayer | 1 | $61 |
| Johnson & Johnson | 4 | $60 |
| Medtronic | 2 | $57 |
| Insulet Corporation | 3 | $56 |
| Tandem Diabetes Care, Inc. | 3 | $54 |
| Mallinckrodt Enterprises LLC | 2 | $53 |
| UCB, Inc. | 3 | $53 |
| BETA Bionics, Inc. | 2 | $49 |
| Recordati_rare_diseases_inc. | 2 | $41 |
| Shire North American Group Inc | 3 | $40 |
| BD | 2 | $37 |
| Eisai Inc. | 2 | $37 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| Radius Health, Inc. | 1 | $31 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| AbbVie | 2 | $24 |
| Valeritas, Inc. | 1 | $22 |
| Companion Medical, Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Harmony Biosciences LLC | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Merck | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Acorda Therapeutics, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$125
- Korlym$117
- EVENITY$116
- DEXCOM G6 TRANSMITTER$106
- Tresiba$102
How this compares
$4,353 in reported general payments places this provider in the 75th percentile of 30 endocrinology, diabetes & metabolism providers in Delaware.
See all endocrinology, diabetes & metabolism providers in Delaware →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 288 | $561,708 |
| MounjaroTirzepatide | 306 | $460,514 |
| JardianceEmpagliflozin | 291 | $412,165 |
| RybelsusSemaglutide | 80 | $157,746 |
| FarxigaDapagliflozin Propanediol | 104 | $140,347 |
| Tresiba Flextouch U-100Insulin Degludec | 165 | $123,791 |
| TrulicityDulaglutide | 55 | $107,353 |
| Tresiba Flextouch U-200Insulin Degludec | 88 | $95,224 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 35 | $57,690 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 47 | $52,882 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $50,291 |
| JanuviaSitagliptin Phosphate | 27 | $34,407 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 78 | $34,157 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 32 | $32,149 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 20 | $28,942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $827 | $732,027393 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $506 | $573,385374 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $158 | $441,107311 claims |
| AstraZenecaFarxiga | $271 | $140,347104 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $355 | $52,88247 claims |
| MerckJanuvia | $19 | $34,40727 claims |
| AbbVieSynthroid | $24 | $10,551142 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $4,794442 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 30 endocrinology, diabetes & metabolism providers in Delaware.
Other endocrinology, diabetes & metabolism in Millsboro
- Joanna KhatibMillsboro$7K
- Abhigna KulkarniMillsboro$2K
- Ripudaman HundalNewark$370K
- Nira MadisiMilford$23K
- Francisco PadillaSeaford$22K
- Reetu SinghLewes$9K
- Chitra ChoudharyDover$5K
- Sheetal BulchandaniNewark$4K
- Avinash RavipatiLewes$3K
- Marc LaufgrabenNewark$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.